mRNA癌症疫苗取得突破进展,莫德纳股价大涨

REBECCA ROBBINS
莫德纳位于马萨诸塞州剑桥市总部的一间实验室,摄于2024年。 Adam Glanzman/Bloomberg

Covid vaccines made Moderna a household name, but the company’s fortunes cratered as demand for the shots plummeted. Hostility from the Trump administration also spooked investors. As of Tuesday, the company’s stock had fallen nearly 90 percent from its peak, a loss of $170 billion in market value.

新冠疫苗曾让莫德纳家喻户晓,但随着需求骤降,这家公司的境况也急转直下。特朗普政府的敌意态度也让投资者感到不安。截至周二,莫德纳股价已较峰值下跌近90%,市值蒸发1700亿美元。

All the while, the company was quietly mounting a comeback in cancer.

与此同时,这家公司一直在癌症领域悄悄布局,谋求东山再起。

On Wednesday, those efforts began to pay off in a big way. Moderna and the big drugmaker Merck reported that their experimental cancer vaccine extended the time before melanoma recurred in a clinical trial — the first late-stage study of its kind to succeed. The two drugmakers announced their success in news releases, without providing numbers that would indicate how much patients had benefited. Moderna’s stock closed up 177 percent on Wednesday.

周三,这些努力开始获得巨大回报。莫德纳和制药巨头默克宣布,双方合作的一款实验性癌症疫苗在一项临床试验中延缓了黑色素瘤患者的复发——这是同类疫苗首次在后期临床试验中取得成功。两家药企通过新闻稿公布了这一成果,但未提供显示患者获益程度的具体数据。周三,莫德纳股价收盘大涨177%。

The investors were betting that Moderna could help jump-start a new approach to treating certain cancers. The experimental vaccine uses the same messenger RNA, or mRNA, technology that powered Moderna’s Covid-19 shot, but it works differently to treat cancer. Tailored to each patient’s tumor genetics, the vaccine delivers instructions to produce a fragment of a tumor to teach the body’s immune system to attack the cancer.

投资者押注的是,莫德纳或许有望帮助开启一种治疗某些癌症的新路径。这款实验性疫苗采用了与莫德纳新冠疫苗相同的信使核糖核酸(mRNA)技术,但治疗癌症的方式有所不同。疫苗根据每位患者肿瘤的基因特征量身定制,通过传递指令让身体产生肿瘤片段,从而训练免疫系统攻击癌细胞。

Cancer vaccines using mRNA could become a hugely lucrative business, if the approach works across cancer types. Cutting-edge cancer drugs typically cost several hundred thousand dollars a year.

如果这项技术对多种癌症类型都有效,那么mRNA癌症疫苗有望成为一项利润丰厚的业务。当前最前沿的抗癌药物通常每年要花费数十万美元。

For Moderna, cancer “is by far the most significant pipeline opportunity,” said Tyler Van Buren, an analyst at the Wall Street bank TD Cowen.

华尔街投行TD Cowen的分析师泰勒·范布伦说,对莫德纳而言,癌症“无疑是其研发管线中最重要的机会”。

Moderna’s chief executive, Stéphane Bancel, said on CNBC on Wednesday that the company’s work on the cancer vaccine was its latest effort to “take very big, scientific clinical bets.”

莫德纳首席执行官斯特凡纳·邦塞尔周三接受CNBC采访时说,公司在癌症疫苗方面的研发是“在科学临床项目上进行大胆押注”的最新尝试。

The prospect of using mRNA vaccines to treat cancer has tantalized researchers for decades. But momentum in the field has accelerated only recently, as manufacturing and other technology has improved, thanks in part to investments during the pandemic.

利用mRNA疫苗治疗癌症的前景已让研究人员憧憬了数十年。但该领域直到最近才加速发展,部分原因在于疫情期间的投资推动了制造工艺及其他技术的进步。

As of last year, more than 60 cancer vaccines using mRNA or similar technology were in development, being tested in more than 120 clinical trials, according to one count. Many of those studies are funded by philanthropies, the government and smaller biotechnology companies.

据一项统计,截至去年,已有60多种采用mRNA或类似技术的癌症疫苗正在研发中,并正在接受超过120项临床试验的测试。其中许多研究由慈善机构、政府和规模较小的生物科技公司提供资金。

Four major drugmakers are leading the development efforts. Two are Moderna and Merck, whose collaboration on the approach dates back a decade; they are also testing the same vaccine as a therapy for cancers of the lung, kidney and bladder. (In the study whose results were announced on Wednesday, the cancer vaccine was given in combination with Keytruda, Merck’s blockbuster cancer immunotherapy.)

目前有四家大型药企领跑这一领域的研发。其中两家就是莫德纳和默克,它们在这一领域的合作可以追溯到十年前;它们还在测试同一款疫苗用于治疗肺癌、肾癌和膀胱癌。(在周三公布结果的那项试验中,测试对象在使用这款癌症疫苗的同时,还使用了默克公司的重磅抗癌免疫药物Keytruda。)

BioNTech, another developer of an mRNA vaccine for Covid, is working with Roche’s Genentech unit to develop a vaccine to treat cancers of the pancreas and colon. Results from a small safety study of that therapy in pancreatic cancer generated excitement this spring.

另一家新冠mRNA疫苗开发商BioNTech正在与罗氏旗下的基因泰克合作,开发一款用于治疗胰腺癌和结肠癌的疫苗。今年春季公布的一项针对胰腺癌患者的小规模安全性试验结果令人振奋。

The approach has historically been seen as risky. The manufacturing is complex, the politics are fraught and there had been little evidence it would work. Other large major cancer drugmakers, like Pfizer and Bristol Myers Squibb, are not working on mRNA vaccines for cancer.

这种方法过去一直被视为风险很高。其生产流程复杂,相关政治环境复杂,而且此前几乎没有证据证明它能够奏效。其他大型抗癌药企,如辉瑞和百时美施贵宝,目前并没有开展mRNA癌症疫苗的研发。

Under Health Secretary Robert F. Kennedy Jr., the Trump administration has made a series of funding and policy changes hostile to mRNA technology. A year ago, the federal government canceled nearly half a billion dollars’ worth of contracts and other funding for mRNA technology.

在卫生部长小罗伯特·肯尼迪领导下,特朗普政府接连出台针对mRNA技术不利的资金和政策调整。一年前,联邦政府取消了价值近5亿美元的mRNA技术相关合同及其他资金支持。

“Those political headwinds were serious, and it caused a lot of companies to take great pause,” said Jeff Coller, a scientist who works on mRNA at Johns Hopkins University. Dr. Coller advises several small mRNA companies and is on the executive committee of the Alliance for mRNA Medicines, a trade group.

约翰斯·霍普金斯大学从事mRNA研究的科学家杰夫·科勒表示:“这些政治阻力非常大,让许多公司望而却步。”科勒为几家小型mRNA公司提供咨询,同时也是行业组织“mRNA药物联盟”的执行委员会成员。

But the administration has signaled it may be more open when it comes to mRNA for treating cancer. This year, it quietly started a public-private partnership expected to fund clinical trials of different cancer vaccines, including those using mRNA. The Department of Health and Human Services did not return a request for comment on Wednesday about the status of that initiative and how much funding the department has granted.

不过,在将mRNA用于治疗癌症的问题上,特朗普政府释放出的信号可能更为开放。今年,政府悄然启动了一项公私合作项目,预计将为不同癌症疫苗的临床试验提供资金,其中包括采用mRNA技术的疫苗。美国卫生与公众服务部周三未就该项目进展及拨款金额回应置评请求。

Moderna was founded in 2010 in Cambridge, Mass., to develop medicines using mRNA. Its Covid vaccine, its first product, brought in tens of billions of dollars of revenue during the pandemic.

莫德纳于2010年在马萨诸塞州剑桥成立,致力于利用mRNA技术开发药物。其新冠疫苗是公司的第一款产品,在疫情期间带来了数百亿美元的收入。

But as the public and the government soured on its Covid shot, Moderna had hardly anything to replace it with. Over the past few years, Moderna looked for different ways to reinvent itself. It won approvals for mRNA vaccines for respiratory syncytial virus and, most recently, flu. It also explored experimental therapies for rare diseases.

但随着公众和政府对新冠疫苗态度转冷,莫德纳几乎没有替代产品。过去几年,它尝试感觉哦多种转型路径。其针对呼吸道合胞病毒的mRNA疫苗已获批,最近又获批了流感疫苗。公司还探索了针对罕见疾病的实验性疗法。

Last year, the company laid off more than 800 workers, a tenth of its work force. It also lost more than $700 million in contracts to develop a shot to protect humans against bird flu after the Trump administration canceled the agreements. The company shelved vaccines to protect against herpes, chickenpox and shingles.

去年,公司裁员800余人,占员工总数的十分之一。在特朗普政府取消相关协议后,公司损失了超过7亿美元的禽流感疫苗开发合同。它还搁置了针对疱疹、水痘和带状疱疹的疫苗研发。

Even though it had started years before the pandemic, Moderna’s work on mRNA cancer vaccines flew relatively under the radar. In addition to the experimental cancer vaccine it is developing with Merck, Moderna solely owns several others that it is testing in different cancers.

尽管莫德纳早在新冠疫情暴发前就已经开始研发mRNA癌症疫苗,但这项工作相对不受关注。除了与默克合作开发的实验性癌症疫苗之外,莫德纳还独自拥有数款其他癌症疫苗,目前正在进行实验。

“People started to pay attention” as Moderna and Merck began presenting promising results from midstage clinical research, said Andrew Tsai, an analyst at the Wall Street bank Jefferies.

华尔街投行Jefferies分析师安德鲁·蔡(音)表示,随着莫德纳和默克开始公布中期临床研究的积极结果,“人们开始注意到了”这一领域。

Now, Moderna is back in the spotlight. Crucial questions remain: Will the promising results in melanoma, which has repeatedly proved to be more responsive to treatment, hold up in cancers that are tougher to treat? And will the detailed results look as good as the companies made them sound on Wednesday? (The drugmakers said they would present the full data soon at a medical meeting.)

如今,莫德纳重回聚光灯下。但关键问题依然存在:在黑色素瘤这种一再被证明对治疗较为敏感的癌症中取得的积极结果,能否在那些更难治疗的癌症中同样成立?详细的临床数据是否如两家公司周三所说那样出色?(两家药企表示,他们很快将在一次医学会议上公布完整数据。)

But now that an mRNA cancer vaccine appears to have succeeded, Mr. Van Buren of TD Cowen said he anticipated that drugmakers would flock into the technology.

不过,既然一款mRNA癌症疫苗似乎已经取得成功,TD Cowen的范布伦预计,制药企业将纷纷涌入这一技术领域。

“Now that this trial was successful,” he said, “I definitely think we can expect more investment by other pharma companies.”

“既然这项试验已经成功,”他说,“我认为我们完全可以预期,其他制药公司会加大投资。”

Rebecca Robbins是时报记者,主要报道制药行业。她自2015年以来一直从事健康和医学方面的报道。

翻译:杜然

点击查看本文英文版。

内容来自 纽约时报双语版,版权归原作者所有。

阅读原文 ↗

把喜欢的内容,留在你的新标签页。

打开我的订阅